These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
464 related articles for article (PubMed ID: 12694517)
1. The overall effectiveness of prophylaxis in severe haemophilia. Panicker J; Warrier I; Thomas R; Lusher JM Haemophilia; 2003 May; 9(3):272-8. PubMed ID: 12694517 [TBL] [Abstract][Full Text] [Related]
2. [Prevention of joint damage in hemophilic children with early prophylaxis]. Kreuz W; Escuriola Ettingshausen C; Funk M; Pons S; Schmidt H; Kornhuber B Orthopade; 1999 Apr; 28(4):341-6. PubMed ID: 10335528 [TBL] [Abstract][Full Text] [Related]
3. Orthopaedic evaluation in children with severe haemophilia A or B submitted to primary prophylaxis therapy in a coagulopathy treatment centre. De Podestá Haje D; Ono F; De Oliveira GB; Almeida J; De Paula JC; Batista Neto LV; Silva Barros SB Haemophilia; 2011 Mar; 17(2):228-32. PubMed ID: 21070500 [TBL] [Abstract][Full Text] [Related]
4. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China. Wu R; Luke KH; Poon MC; Wu X; Zhang N; Zhao L; Su Y; Zhang J Haemophilia; 2011 Jan; 17(1):70-4. PubMed ID: 20579111 [TBL] [Abstract][Full Text] [Related]
5. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Fischer K; van der Bom JG; Molho P; Negrier C; Mauser-Bunschoten EP; Roosendaal G; De Kleijn P; Grobbee DE; van den Berg HM Haemophilia; 2002 Nov; 8(6):745-52. PubMed ID: 12410642 [TBL] [Abstract][Full Text] [Related]
6. Prophylaxis for severe haemophilia: clinical and economical issues. Fischer K; Van Den Berg M Haemophilia; 2003 Jul; 9(4):376-81. PubMed ID: 12828671 [TBL] [Abstract][Full Text] [Related]
7. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ; Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844 [TBL] [Abstract][Full Text] [Related]
8. Radiologic evaluation of prophylaxis in severe haemophilia. Pettersson H; Nilsson IM; Hedner U; Noréhn K; Ahlberg A Acta Paediatr Scand; 1981 Jul; 70(4):565-70. PubMed ID: 6797235 [TBL] [Abstract][Full Text] [Related]
9. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Steen Carlsson K; Höjgård S; Glomstein A; Lethagen S; Schulman S; Tengborn L; Lindgren A; Berntorp E; Lindgren B Haemophilia; 2003 Sep; 9(5):555-66. PubMed ID: 14511294 [TBL] [Abstract][Full Text] [Related]
10. The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP. Berntorp E Baillieres Clin Haematol; 1996 Jun; 9(2):259-71. PubMed ID: 8800504 [TBL] [Abstract][Full Text] [Related]
11. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan. Taki M; Shirahata A Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841 [TBL] [Abstract][Full Text] [Related]
12. Primary prophylaxis in children with haemophilia. Coppola A; Di Capua M; De Simone C Blood Transfus; 2008 Sep; 6 Suppl 2(Suppl 2):s4-11. PubMed ID: 19105503 [TBL] [Abstract][Full Text] [Related]
13. Low-dose tertiary prophylactic therapy reduces total number of bleeds and improves the ability to perform activities of daily living in adults with severe haemophilia A: a single-centre experience from Beijing. Hua B; Lian X; Li K; Lee A; Poon MC; Zhao Y Blood Coagul Fibrinolysis; 2016 Mar; 27(2):136-40. PubMed ID: 26258677 [TBL] [Abstract][Full Text] [Related]
14. Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25). Meunier S; d'oiron R; Chambost H; Dolimier E; Guillet B; Thromb Res; 2017 Mar; 151():17-22. PubMed ID: 28088606 [TBL] [Abstract][Full Text] [Related]
15. Secondary prophylaxis in adolescent and adult haemophiliacs. Tagliaferri A; Di Perna C; Rivolta GF Blood Transfus; 2008 Sep; 6 Suppl 2(Suppl 2):s17-20. PubMed ID: 19105505 [TBL] [Abstract][Full Text] [Related]
16. Optimizing factor prophylaxis for the haemophilia population: where do we stand? Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380 [TBL] [Abstract][Full Text] [Related]
17. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study. Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137 [TBL] [Abstract][Full Text] [Related]
18. When should prophylactic treatment in patients with haemophilia A and B start?--The German experience. Kreuz W; Escuriola-Ettingshausen C; Funk M; Schmidt H; Kornhuber B Haemophilia; 1998 Jul; 4(4):413-7. PubMed ID: 9873763 [TBL] [Abstract][Full Text] [Related]
19. Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort. Feldman BM; Rivard GE; Babyn P; Wu JKM; Steele M; Poon MC; Card RT; Israels SJ; Laferriere N; Gill K; Chan AK; Carcao M; Klaassen RJ; Cloutier S; Price VE; Dover S; Blanchette VS Lancet Haematol; 2018 Jun; 5(6):e252-e260. PubMed ID: 29731369 [TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Antunes SV; Tangada S; Stasyshyn O; Mamonov V; Phillips J; Guzman-Becerra N; Grigorian A; Ewenstein B; Wong WY Haemophilia; 2014 Jan; 20(1):65-72. PubMed ID: 23910578 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]